Organizational Changes at Illumina Aimed at Growth, New Market Entries | GenomeWeb

NEW YORK (GenomeWeb News) – Illumina today announced sweeping changes to its organization in order to maintain growth in its existing markets and to move into new ones.

In a letter to employees, which was filed with the US Securities and Exchange Commission, Illumina President and CEO Jay Flatley laid out the changes, which include the creation of new business units, new roles for existing managers, and the separation of the president's position from Flatley's continued role as CEO.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.